Combined treatment of γ-tocotrienol with PPARγ antagonists was found to reduced PI3K, phosphorylated PDK-1 (active), and phosphorylated-Akt (active) levels in MCF-7 and MDA-MB-231 breast cancer cells. This evidence concerns the gene PPARG and breast carcinoma.